靶向外周alpha 2A肾上腺素受体作为一种整合癌症治疗与支持性护理的双重获益策略

Background : Emerging evidence highlights sympathetic innervation is a key component of the tumor microenvironment, and that denervation effectively suppresses tumor growth, revealing new therapeutic opportunities (Vera Thiel, Nature 2025). alpha 2A -adrenoceptor (alpha 2A AR) agonists like clonidine are potent regulators of sympathetic activity, and have demonstrated antitumor efficacy (Jingjing Zhu, Nature 2023), yet their application in oncology can be severely limited by the central nervous system (CNS)-mediated adverse effects, including sedation and hypothermia. To overcome this challenge, we developed CC10230, a novel peripherally restricted alpha 2A AR agonist designed to provide sustained antitumor therapy without dose-limiting CNS toxicity. Method : A focused compound library was generated through rational design and screened based on in vitro alpha 2A AR potency, P-gp efflux ratio, and oral bioavailability. Peripheral restriction of the lead compound was confirmed using in vivo distribution pharmacokinetic. Anti-tumor activity was assessed in the MC38 subcutaneous tumor model in mice, and anti-allodynic efficacy was evaluated in the NCTC-2572 cell-induced bone cancer pain model in mice. All clinical observations, including behavior and safety monitoring, were conducted in accordance with CRO's standard operating procedure (SOP). Result : CC10230 was selected as a lead compound based on its high alpha 2A AR activity (EC 50 = 7.5 nM, Ki = 58.1 nM), strong P-gp substrate properties (efflux ratio = 51.0), and a favorable oral bioavailability (44.6%). Pharmacokinetic studies confirmed minimal CNS penetration (Kp,uu,brain < 0.03), markedly lower than that of clonidine, supporting strong peripheral restriction. In the MC38 model, CC10230 (5 mg/kg, b.i.d., p.o.) significantly suppressed tumor growth, achieving a TGI of 62.3% at Day 17. Clonidine (5 mg/kg, b.i.d., p.o.) as a positive control also achieved significant TGI but was poorly tolerated, causing pronounced somnolence, hypothermia, and 18.1% body weight loss. In contrast, CC10230 showed no tolerability issues. Additionally, CC10230 exhibited robust efficacy in cancer pain model, confirming its dual therapeutic benefits. Conclusion : These findings establish peripheral alpha 2A AR activation as a promising two-pronged translational strategy for integrated oncology care, simultaneously inhibiting tumor progression and alleviating cancer-related pain while circumventing CNS-mediated side effects. The favorable safety profile of CC10230 supports its potential for sustained antitumor therapy without the tolerability limitations of conventional alpha 2A AR agonists.